| Authors: |
Schmid D; Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Microbiology & Immunobiology, Harvard Medical School, Boston, MA, 02215, USA., Park CG; Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Microbiology & Immunobiology, Harvard Medical School, Boston, MA, 02215, USA., Hartl CA; Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Subedi N; Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Cartwright AN; Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Puerto RB; Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Zheng Y; Department of Biological Engineering, MIT, Cambridge, MA, 02139, USA.; Koch Institute for Integrative Cancer Research, Cambridge, MA, 02139, USA., Maiarana J; Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Freeman GJ; Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Wucherpfennig KW; Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Irvine DJ; Department of Biological Engineering, MIT, Cambridge, MA, 02139, USA.; Koch Institute for Integrative Cancer Research, Cambridge, MA, 02139, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, 20815, USA., Goldberg MS; Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. michael_goldberg1@dfci.harvard.edu.; Department of Microbiology & Immunobiology, Harvard Medical School, Boston, MA, 02215, USA. michael_goldberg1@dfci.harvard.edu. |